Trial Radar AI
Clinical Trial NCT06885905 (CAPSULE) for Chronic Pulmonary Aspergillosis is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being (CAPSULE) 100 Novel Treatment

Recruiting
Clinical Trial NCT06885905 (CAPSULE) is an observational study for Chronic Pulmonary Aspergillosis that is recruiting. It started on 27 November 2024 with plans to enroll 100 participants. Led by Imperial College London, it is expected to complete by 23 April 2026. The latest data from ClinicalTrials.gov was last updated on 20 March 2025.
Brief Summary
To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.
Official Title

Impact of Chronic Pulmonary Aspergillosis (CPA) on Health Status and Well-being

Conditions
Chronic Pulmonary Aspergillosis
Other Study IDs
  • CAPSULE
  • 23IC8471
NCT ID Number
NCT06885905
Start Date (Actual)
2024-11-27
Last Update Posted
2025-03-20
Completion Date (Estimated)
2026-04-23
Enrollment (Estimated)
100
Study Type
Observational
Status
Recruiting
Keywords
CPA
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.
To develop and validate a novel disease-specific health-related quality of life (HRQoL) measure in chronic pulmonary aspergillosis (CPA): The Chronic Pulmonary Aspergillosis Health Assessment Questionnaire (CPA-HAQ)
30 months
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.
Testing the usability of a newly developed CPA-HAQ measure.
30 months
Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.
Correlating how HRQoL outcomes relate to existing disease prognostic markers.
30 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  1. All patients >/= 18 years old and able to provide informed consent
  2. Patients with a diagnosis of chronic pulmonary aspergillosis
  3. To speak and understand English
  4. Able to provide informed consent
Imperial College London logoImperial College London
  • Manchester University NHS Foundation Trust logoManchester University NHS Foundation Trust
  • Tayside Medical Science Centre logoTayside Medical Science Centre
Study Central Contact
Contact: Dareen Marghlani, MSc, [email protected], [email protected]
Contact: Anand Shah, PhD, [email protected]
3 Study Locations in 1 Countries
Ninewells Hospital & Medical School, Dundee, DD1 9SY, United Kingdom
David Connell, PhD FRCP Edin, Contact, [email protected], [email protected]
David Connell, PhD FRCP Edin, Principal Investigator
Recruiting
Imperial College London, London, United Kingdom
Dareen Marghlani, MSc, Contact, [email protected], [email protected]
Anand Shah, PhD, Principal Investigator
Recruiting
Manchester NHS Foundation Trust, Manchester, United Kingdom
Chris Kosmidis, PhD, Contact, [email protected], [email protected]
Chris Kosmidis, PhD, Principal Investigator
Recruiting